GILEAD SCIENCES, INC. (GILD) FY2026 Q1 P&L / Income Statement

Income StatementCash FlowBalance Sheet

Revenue by Product and Service by Geography

2026-01-01 to 2026-03-31

Swipe to see the full flow
GILEAD SCIENCES, INC. (GILD) FY2026 Q1 P&L / Income StatementIncome statement for 2026-01-01 through 2026-03-31. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.SOURCESREVENUE RECONCILIATIONREVENUEGROSSOPERATINGPRE-TAXNETProduct sales - UNITED STATESTotal HIV - UNITED STATESBiktarvy - UNITED STATESProduct sales - EuropeProduct sales - Rest of WorldDescovy - UNITED STATESTotal HIV - EuropeBiktarvy - EuropeTotal HIV - Rest of WorldTotal Oncology - UNITED STATESTotal Liver Disease - UNITED STATESBiktarvy - Rest of WorldTotal Oncology - EuropeTrodelvy - UNITED STATESTotal Liver Disease - Rest of WorldGenvoya - UNITED STATESTotal Cell Therapy - EuropeTotal Liver Disease - EuropeYeztugo - UNITED STATESOdefsey - UNITED STATESTotal Cell Therapy - UNITED STATESYescarta - EuropeSofosbuvir/Velpatasvir - UNITED STATESVemlidy - Rest of WorldTotal Oncology - Rest of WorldYescarta - UNITED STATESLivdelzi - UNITED STATESVeklury - UNITED STATESSymtuza - Revenue share - UNITED STATESTrodelvy - EuropeVemlidy - UNITED STATESTotal Other - Rest of WorldSofosbuvir/Velpatasvir - Rest of WorldTotal Cell Therapy - Rest of WorldAmBisome - Rest of WorldTotal Other - EuropeYescarta - Rest of WorldSofosbuvir/Velpatasvir - EuropeOdefsey - EuropeAmBisome - EuropeTrodelvy - Rest of WorldTotal Other - UNITED STATESTecartus - EuropeGenvoya - EuropeTecartus - UNITED STATESSymtuza - Revenue share - EuropeDescovy - Rest of WorldDescovy - EuropeLivdelzi - EuropeVeklury - Rest of WorldGenvoya - Rest of WorldVeklury - EuropeVemlidy - EuropeOdefsey - Rest of WorldTecartus - Rest of WorldRoyalty, contract and other revenues - EuropeYeztugo - Rest of WorldAmBisome - UNITED STATESRoyalty, contract and other revenues - Rest of WorldSymtuza - Revenue share - Rest of WorldOther Liver Disease - EuropeOther - UNITED STATESOther HIV - UNITED STATESOther HIV - EuropeOther Liver Disease - Rest of WorldOther Liver Disease - UNITED STATESOther - Rest of WorldOther HIV - Rest of WorldOther - EuropeTotal revenuesRevenue before reconciliation (calculated)Components above reported revenue (calculated)Gross profit (calculated)Cost of goods soldOperating incomeOperating expenses (calculated)Income before income taxesOther income (expense), net (calculated)Net incomeIncome tax expenseRevenue before reconciliation (calculated)Revenue beforereconciliation(calculated)$21.12 BGross profit (calculated)Gross profit(calculated)$5.52 BTotal revenuesTotal revenues$6.96 BOperating incomeOperating income$2.59 BIncome before income taxesPretax income$2.58 BNet incomeNet income$2.02 BProduct sales - UNITED STATESProduct sales -UNITED STATES$4.93 BOperating expenses (calculated)Operating expenses(calculated)$2.93 BTotal HIV - UNITED STATESTotal HIV -UNITED STATES$4.00 BIncome tax expenseIncome tax expense$559.00 MCost of goods soldCost of goods sold$1.45 BOther income (expense), net (calculated)Other income,net (calculated)−$6.00 MBiktarvy - UNITED STATESBiktarvy -UNITED STATES$2.57 BProduct sales - EuropeProduct sales - Europe$1.14 BProduct sales - Rest of WorldProduct sales- Rest of World$883.00 MDescovy - UNITED STATESDescovy -UNITED STATES$761.00 MComponents above reported revenue (calculated)Components abovereported revenue(calculated)−$14.16 BTotal HIV - EuropeTotal HIV - Europe$607.00 MBiktarvy - EuropeBiktarvy - Europe$437.00 MTotal HIV - Rest of WorldTotal HIV -Rest of World$419.00 MTotal Oncology - UNITED STATESTotal Oncology- UNITED STATES$403.00 MTotal Liver Disease - UNITED STATESTotal Liver Disease- UNITED STATES$362.00 MBiktarvy - Rest of WorldBiktarvy - Rest of World$352.00 MTotal Oncology - EuropeTotal Oncology- Europe$278.00 MTrodelvy - UNITED STATESTrodelvy -UNITED STATES$253.00 MTotal Liver Disease - Rest of WorldTotal Liver Disease- Rest of World$235.00 MGenvoya - UNITED STATESGenvoya -UNITED STATES$215.00 MTotal Cell Therapy - EuropeTotal CellTherapy - Europe$183.00 MTotal Liver Disease - EuropeTotal LiverDisease - Europe$170.00 MYeztugo - UNITED STATESYeztugo -UNITED STATES$158.00 MOdefsey - UNITED STATESOdefsey -UNITED STATES$153.00 MTotal Cell Therapy - UNITED STATESTotal Cell Therapy- UNITED STATES$150.00 MYescarta - EuropeYescarta - Europe$146.00 MSofosbuvir/Velpatasvir - UNITED STATESSofosbuvir/Velpatasvir- UNITED STATES$141.00 MVemlidy - Rest of WorldVemlidy - Rest of World$132.00 MTotal Oncology - Rest of WorldTotal Oncology- Rest of World$129.00 MYescarta - UNITED STATESYescarta -UNITED STATES$120.00 MLivdelzi - UNITED STATESLivdelzi -UNITED STATES$115.00 MVeklury - UNITED STATESVeklury -UNITED STATES$112.00 MSymtuza - Revenue share - UNITED STATESSymtuza - Revenueshare - UNITED STATES$107.00 MTrodelvy - EuropeTrodelvy - Europe$95.00 MVemlidy - UNITED STATESVemlidy -UNITED STATES$91.00 MTotal Other - Rest of WorldTotal Other -Rest of World$83.00 MSofosbuvir/Velpatasvir - Rest of WorldSofosbuvir/Velpatasvir- Rest of World$82.00 MTotal Cell Therapy - Rest of WorldTotal Cell Therapy- Rest of World$74.00 MAmBisome - Rest of WorldAmBisome -Rest of World$72.00 MTotal Other - EuropeTotal Other - Europe$67.00 MYescarta - Rest of WorldYescarta -Rest of World$67.00 MSofosbuvir/Velpatasvir - EuropeSofosbuvir/Velpatasvir- Europe$60.00 MOdefsey - EuropeOdefsey - Europe$59.00 MAmBisome - EuropeAmBisome - Europe$59.00 MTrodelvy - Rest of WorldTrodelvy -Rest of World$54.00 MTotal Other - UNITED STATESTotal Other -UNITED STATES$46.00 MTecartus - EuropeTecartus - Europe$37.00 MGenvoya - EuropeGenvoya - Europe$33.00 MTecartus - UNITED STATESTecartus -UNITED STATES$30.00 MSymtuza - Revenue share - EuropeSymtuza - Revenueshare - Europe$28.00 MDescovy - Rest of WorldDescovy -Rest of World$23.00 MDescovy - EuropeDescovy - Europe$23.00 MLivdelzi - EuropeLivdelzi - Europe$18.00 MVeklury - Rest of WorldVeklury - Rest of World$18.00 MGenvoya - Rest of WorldGenvoya -Rest of World$16.00 MVeklury - EuropeVeklury - Europe$14.00 MVemlidy - EuropeVemlidy - Europe$13.00 MOdefsey - Rest of WorldOdefsey - Rest of World$9.00 MTecartus - Rest of WorldTecartus -Rest of World$8.00 MRoyalty, contract and other revenues - EuropeRoyalty, contractand otherrevenues - Europe$8.00 MYeztugo - Rest of WorldYeztugo - Rest of World$7.00 MAmBisome - UNITED STATESAmBisome -UNITED STATES$7.00 MRoyalty, contract and other revenues - Rest of WorldRoyalty, contractand other revenues- Rest of World$6.00 MSymtuza - Revenue share - Rest of WorldSymtuza - Revenueshare - Rest of World$3.00 MOther Liver Disease - EuropeOther LiverDisease - Europe$78.00 MOther - UNITED STATESOther - UNITED STATES$39.00 MOther HIV - UNITED STATESOther HIV -UNITED STATES$36.00 MOther HIV - EuropeOther HIV - Europe$27.00 MOther Liver Disease - Rest of WorldOther Liver Disease- Rest of World$21.00 MOther Liver Disease - UNITED STATESOther Liver Disease- UNITED STATES$15.00 MOther - Rest of WorldOther - Rest of World$11.00 MOther HIV - Rest of WorldOther HIV -Rest of World$9.00 MOther - EuropeOther - Europe$8.00 M
Chart details

GILEAD SCIENCES, INC. (GILD) FY2026 Q1 P&L / Income Statement

Income statement for 2026-01-01 through 2026-03-31. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenues
6,960,000,000 US dollars
Cost of goods sold
1,445,000,000 US dollars
Gross profit (calculated)
5,515,000,000 US dollars
Operating expenses (calculated)
2,929,000,000 US dollars
Operating income
2,586,000,000 US dollars
Other income (expense), net (calculated)
negative 6,000,000 US dollars
Income before income taxes
2,580,000,000 US dollars
Income tax expense
559,000,000 US dollars
Net income
2,021,000,000 US dollars
Tecartus - UNITED STATES
30,000,000 US dollars
Tecartus - Rest of World
8,000,000 US dollars
Tecartus - Europe
37,000,000 US dollars
Total Cell Therapy - UNITED STATES
150,000,000 US dollars
Total Cell Therapy - Rest of World
74,000,000 US dollars
Total Cell Therapy - Europe
183,000,000 US dollars
Total HIV - UNITED STATES
4,004,000,000 US dollars
Total HIV - Rest of World
419,000,000 US dollars
Total HIV - Europe
607,000,000 US dollars
Biktarvy - UNITED STATES
2,573,000,000 US dollars
Biktarvy - Rest of World
352,000,000 US dollars
Biktarvy - Europe
437,000,000 US dollars
Descovy - UNITED STATES
761,000,000 US dollars
Descovy - Rest of World
23,000,000 US dollars
Descovy - Europe
23,000,000 US dollars
Genvoya - UNITED STATES
215,000,000 US dollars
Genvoya - Rest of World
16,000,000 US dollars
Genvoya - Europe
33,000,000 US dollars
Odefsey - UNITED STATES
153,000,000 US dollars
Odefsey - Rest of World
9,000,000 US dollars
Odefsey - Europe
59,000,000 US dollars
Other HIV - UNITED STATES
36,000,000 US dollars
Other HIV - Rest of World
9,000,000 US dollars
Other HIV - Europe
27,000,000 US dollars
Symtuza - Revenue share - UNITED STATES
107,000,000 US dollars
Symtuza - Revenue share - Rest of World
3,000,000 US dollars
Symtuza - Revenue share - Europe
28,000,000 US dollars
Yeztugo - UNITED STATES
158,000,000 US dollars
Yeztugo - Rest of World
7,000,000 US dollars
Yeztugo - Europe
0 US dollars
Total Liver Disease - UNITED STATES
362,000,000 US dollars
Total Liver Disease - Rest of World
235,000,000 US dollars
Total Liver Disease - Europe
170,000,000 US dollars
Livdelzi - UNITED STATES
115,000,000 US dollars
Livdelzi - Rest of World
0 US dollars
Livdelzi - Europe
18,000,000 US dollars
Other Liver Disease - UNITED STATES
15,000,000 US dollars
Other Liver Disease - Rest of World
21,000,000 US dollars
Other Liver Disease - Europe
78,000,000 US dollars
Sofosbuvir/Velpatasvir - UNITED STATES
141,000,000 US dollars
Sofosbuvir/Velpatasvir - Rest of World
82,000,000 US dollars
Sofosbuvir/Velpatasvir - Europe
60,000,000 US dollars
Vemlidy - UNITED STATES
91,000,000 US dollars
Vemlidy - Rest of World
132,000,000 US dollars
Vemlidy - Europe
13,000,000 US dollars
Total Oncology - UNITED STATES
403,000,000 US dollars
Total Oncology - Rest of World
129,000,000 US dollars
Total Oncology - Europe
278,000,000 US dollars
AmBisome - UNITED STATES
7,000,000 US dollars
AmBisome - Rest of World
72,000,000 US dollars
AmBisome - Europe
59,000,000 US dollars
Other - UNITED STATES
39,000,000 US dollars
Other - Rest of World
11,000,000 US dollars
Other - Europe
8,000,000 US dollars
Total Other - UNITED STATES
46,000,000 US dollars
Total Other - Rest of World
83,000,000 US dollars
Total Other - Europe
67,000,000 US dollars
Yescarta - UNITED STATES
120,000,000 US dollars
Yescarta - Rest of World
67,000,000 US dollars
Yescarta - Europe
146,000,000 US dollars
Royalty, contract and other revenues - UNITED STATES
0 US dollars
Royalty, contract and other revenues - Rest of World
6,000,000 US dollars
Royalty, contract and other revenues - Europe
8,000,000 US dollars
Trodelvy - UNITED STATES
253,000,000 US dollars
Trodelvy - Rest of World
54,000,000 US dollars
Trodelvy - Europe
95,000,000 US dollars
Veklury - UNITED STATES
112,000,000 US dollars
Veklury - Rest of World
18,000,000 US dollars
Veklury - Europe
14,000,000 US dollars
Product sales - UNITED STATES
4,926,000,000 US dollars
Product sales - Rest of World
883,000,000 US dollars
Product sales - Europe
1,137,000,000 US dollars
Selling, general and administrative expenses
1,451,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn.
Acquired in-process research and development expenses
107,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn.
Research and development expenses
1,372,000,000 US dollars. Source detail retained; this breakdown has not reconciled exactly and is not drawn.
Revenue before reconciliation (calculated)
21,115,000,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation.
Components above reported revenue (calculated)
negative 14,155,000,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item.

Chart connections

  • Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
  • Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
  • Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.
GILEAD SCIENCES, INC. (GILD) FY2026 Q1 P&L / Income Statement Sankey chart, Product and service — Product and Service by Geographical view
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Gross margin

79.2%

Gross profit / revenue

Operating margin

37.2%

Operating profit / revenue

Cash conversion

125.9%

Operating cash / net income, same period

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!